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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not Topiramate is
effective in the prevention of pediatric migraines.
Study Design: Review of three English language randomized control trials published in 2005, 2007,
and 2009
Data sources: Three double-blind, placebo-controlled, randomized trials comparing various doses of
Topiramate to placebo were found using PubMed, OVID, and Cochrane Library databases.
Outcome(s) Measured: The frequency of migraines in patients under the age of 18 years old was
documented with headache diaries. The patient’s parent would record the number, severity, duration,
associated symptoms, and use of acute abortive medications
Results: Three randomized, controlled studies comparing topiramate to a placebo pill were reviewed.
The Lakshmi study found that topiramate was effective in preventing pediatric migraines. School
absenteeism was also recorded and was found to decrease with topiramate use. The Lewis study
illustrated statistically significant improvement in the number of migraines per month in the pediatric
population. The Winner Study was the only RCT that revealed a reduction of migraines in the
treatment group that was not statistically significant. The most common adverse effects of topiramate
were weight loss, paresthesias, and anorexia.
Conclusion: Topiramate is a safe and effective prophylactic medication for the prevention of
migraines in children up to 18 years of age.
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INTRODUCTION
Migraines are the second most common cause of headaches in the general population.1
They can be characterized as periodic, unilateral, pulsatile headaches that usually onset in
childhood or adolescence. The migraine can last from 1-48 hours.2 Migraines can be triggered
by sleep deprivation, certain foods, or irregular eating patterns. There are a variety of
medications that have proven to be effective in treating migraines. Some people suffer from
migraines frequently and it can affect their ability to function in everyday life.
The exact cause of migraines is unknown. It is hypothesized that the brain is in a constant
state of neuronal hyperexcitability and a series of neural and vascular events causes the migraine.
One theory centers on the activation of vasoactive neuropeptides which leads to dilation of the
blood vessels.1 Pharmacologic data concludes that neurotransmitters known as 5hydroxytyrptamine (5-HT; also known as serotonin) and dopamine are involved in migraines.
Data reveals that when 5-HT receptors are activated by medication, it can abort the migraine. In
addition, it was discovered that migraine symptoms can be induced by dopaminergic
stimulation.1
Headache is one of the most common complaints in pediatric medicine. Therefore, the
Physician Assistant should be aware of its prevalence, symptoms, and treatment options. The
medical history of the patient is pertinent to the diagnosis. The family history is positive for
vascular, migrainous headaches in 75% of patients.2 The incidence of pediatric migraines ranges
depending on the age of the child. Migraines affect 10.6% of children between the ages of 5 and
15 years old and 28% of adolescents between the ages of 15-19 years old.3 Symptoms typically
include headache, nausea, vomiting, abdominal pain, photophobia, phonophobia, vertigo,
lightheadedness, fatigue, and changes in mood. In younger children, the headache is described as
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bitemporal whereas in adolescents the headache is described as a unilateral, throbbing headache.
Some may experience an aura, which can be a visual or focal disturbance such as zigzags of light
or paresthesias. It is more common for pediatric patients to have migraines without aura. The
International Headache Society (IHS) has proposed diagnostic criteria for the diagnosis of
migraines. For pediatric migraines without an aura, the criteria consists of having at least 5
attacks that have the following qualities: headache lasting 1-48 hours, headache with at least two
of the following: bilateral/unilateral location, pulsating quality, moderate to severe intensity, and
aggravation by routine physical activity, and during the headache, the patient must experience
one of the following: nausea, vomiting, photophobia, or phonophobia.2 The IHS diagnostic
criteria for migraines with aura consists of having at least two attacks with three of the following:
one or more fully reversible aura symptoms indicating focal cortical and/or brainstem
dysfunction, at least one aura developing gradually over more than 4 min or 2 or more symptoms
occurring in succession, no auras lasting more than 60 min, and the headache follows in less than
60 minutes.2
There are many different treatment options available for migraines. Ibuprofen 10 mg/kg
with 40-65 mg of caffeine or 65 mg of Midrin is considered the gold standard therapy to treat
migraines in pediatric patients.2 For severe headaches that do not respond to that treatment
option, triptans are generally used. These medications are not as effective if taken 30 minutes
after the start of the migraine.2 In addition, they should not be used in younger children. If
children are having recurrent migraines, one should consider preventative therapies. Prophylactic
medications include topiramate, propranolol, amitriptyline, cyproheptadine, or valproate.4 There
have not been many studies conducted supporting their efficacy.
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One study determined that 329,000 school days were lost per month due to migraines.4
Statistics from the Agency for Healthcare Research and Quality reveal that in 2009, the average
healthcare cost for children who present to hospitals with headaches, including migraine is
$4,607.5 The same agency revealed there were 7,699 visits to the hospital due to headaches,
including migraines in children.5 No data was available on the cost of migraines to the patient or
the health care system.
This paper evaluates three double-blind, placebo-controlled, randomized trials comparing
the efficacy of Topiramate in preventing migraines in children under the age of 18 years old. The
mechanism of topiramate is unknown. It is hypothesized that it works by blocking the voltagedependant sodium channels and it potentiates an inhibitory neurotransmitter, known as GABA.6
Topiramate is already FDA-approved for prevention of migraines in adults. There are not many
other studies that analyzed the efficacy and safety of topiramate as a migraine prophylactic
medication for children. 6 Topiramate is frequently used as an anti-epileptic medication. It is
FDA approved for use in children aged 2 years or older.6 Generally, the dose of topiramate is
larger when used as an anticonvulsant. The maximum dose given to children is 200mg twice a
day.6
This method of treatment is being proposed because there are no studies supporting the
efficacy of preventative medications for pediatric migraines. It would be more effective for a
health care practitioner to prevent the migraine and improve the quality of life for the patient. It
would decrease the number of office visits. In addition, it may be discovered that prophylactic
medications are better tolerated than the abortive medications for migraines. The treatment
medications have to be monitored
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OBJECTIVE
The objective of this systematic review is to determine whether or not topiramate is
effective in preventing pediatric migraines.
METHODS
Specific selection criteria of three double-blind, placebo-controlled randomized control
trials (RCT) were used for this review. The populations of these studies were children under the
age of 18 years old who are affected with frequent migraines. The interventions utilized in each
RCT were various doses of Topiramate, starting at 15 mg/day up to 200mg/day orally.
Comparisons were made between the various doses to the placebo. Outcomes measured in each
study were based on patient oriented evidence that matters (POEMs). The outcome in each study
was the reduction of the frequency of pediatric migraines using the International Headache
Society (IHS) criteria.
Key words that were used in the searches were “Topiramate”, “migraines”, “pediatric”,
and “prevention”. All articles were published in the English language and were published in
peer-reviewed journals. The author researched the studies through PubMed, OVID, and the
Cochrane Library Database. The author narrowed down the articles based on relevance and
selected the articles based on POEMs. Inclusion criteria consisted of randomized control trials
published after 1996 with the participants under the age of 18 years olds who met the IHS
criteria. Exclusion criteria consisted of studies published before 1996, participants over the age
of 18 years old, or articles with disease-oriented evidence (DOE). The statistics used in the
studies were ANCOVA and p-values with a value <0.05 being statistically significant.
Demographics and characteristics of the studies are presented in Table 1.
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Table 1: Characteristics and Demographics of the Subjects
Study

Type

#
pts

Inclusion Criteria

Exclusion Criteria

Withdrawn

Interventions

141

Age
in
years
12-17

Lewis et
al.
(2009)3

Double
blind,
parallel
group
RCT

Pts already on
topiramate or
failure of
topiramate; Pts
who overused
acute meds; Pts
with BMI
>40kg/m2 or
>200lb.

38

Placebo,
Topiramate
50mg/day,
Topiramate
100 mg/day

Double
blind
RCT

44

8-14

Patients (Pts) who
have 3-12 migraines
on 14 headache days
per month; Period of
symptoms lasted up
to 24 hours;
Pts who required
preventative
medicine but had
previous failure; Pts
>5th percentile in
body weight
Pts who met IHS
criteria for migraine
with or without aura,
with a frequency of
2 or more headaches
a month for 3
months

Lakshmi
et al.
(2007)7

2

Placebo,
Topiramate
in various
doses up to
100mg/day

Double
Blind
RCT

162

6-15

Pts who had other
types of
headaches; Pts
with other
comorbid
conditions; Pts
who were already
on migraine
prophylaxis
Children 6-15 who
Pts had cluster
met the IHS criteria headaches, chronic
of pediatric migraine migraine, or more
with or without aura than 15 headache
and weighed more
days during the
than 44 lbs. Pts
baseline phase. Pts
experienced an avg
who used
of 3-10 migraine
analgesics > 12
days per month.
days per month or
Females had to be
used
premenarchal or on
ergots/triptans >8
birth control for >1
days per month.
month prior to
Pts who had
enrollment.
previos history of
topiramate or
previous failure of
>2 migraine
preventative
medications

Winner
et al.
(2005)8

31

Placebo,
Topiramate
in various
doses up to
2.0mg/kg per
day
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OUTCOMES
In all three studies, the researchers evaluated patient oriented evidence reflecting the
efficacy of the medication. Headache diaries were used to record the number, severity, and
duration of migraine headaches. Associated symptoms and use of acute abortive medications
were also recorded. The diaries were reviewed every 4 weeks.
RESULTS
The three randomized control trials in this systematic review compared various doses of
topiramate to placebo. The results pertaining to the primary outcomes were presented as
continuous data in all three studies. Therefore, the continuous data could not be converted into
dichotomous data.
The Lakshmi et al. study used a randomized, double-blind, placebo-controlled study to
compare the number of migraines at baseline versus the number of migraines that occurred while
the subject was taking topiramate over a three month maintenance period. The baseline period
was 4 weeks long, in which the topiramate was titrated in 25mg increments per week. Forty two
children completed the treatment per protocol. The primary outcome was measured based on the
patient provided data in the headache diaries, which measured the frequency of the migraines.
The results of the study revealed that there was a decrease in the mean monthly migraine
frequency from 16.14(±9.35) at baseline to 4.27(±1.95) at the end of the study in the topiramate
group. Alternatively, there was a smaller decrease in the mean monthly migraine frequency from
13.38(±7.48) to 7.48(±5.94) at the end of the study in the placebo group.7 The efficacy analysis
also revealed that the mean percentage reduction in monthly migraine frequency had a p-value of
.02 and was deemed statistically significant. In addition, it was determined that there was a
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greater than 50% reduction in monthly migraine days in subjects who were taking topiramate.
Results may be seen below in Table 2.
Table 2: Efficacy of Topiramate in the Lakshmi et al. Study

Mean monthly migraine
frequency at baseline
Mean monthly migraine
frequency after 3 month
maintenance period
Mean percentage reduction in
migraine frequency

Topiramate 100mg (±SD)

Placebo

16.14 (±9.35)

13.38 (±7.48)

4.27 (±1.95)

7.48 (±5.94)

95.2%

52.4%

The Lewis et al. study was a randomized, double-blind, placebo-controlled, parallelgroup study performed to evaluate the safety and efficacy of two dosages of topiramate as a
preventative treatment in adolescents. There was a pre-treatment phase that lasted up to 9 weeks,
a double-blind phase that lasted 16 weeks, and a taper/exit phase lasting up to 6 weeks. Subjects
who completed the pre-treatment phase and had all the entry criteria were randomly assigned to a
50mg topiramate/day group, 100mg topiramate/day group, or a placebo group. The primary
efficacy end point was the percent reduction in the monthly migraine frequency over the 12 week
double-blind treatment phase. The researchers calculated the monthly migraine attack rate by
multiplying the attack count by 28 and dividing by the number of the days in the period. The
percent reduction was calculated using the formula: 100 X [B-D]/B, where B is the migraine
attack rate during baseline and D is the migraine attack rate during the 12 week double-blind
treatment period.3 The researchers stated that a positive value would indicate a reduction from
baseline. The efficacy analysis was performed on the intention-to-treat (ITT) population, which
included all subjects who received one or more doses of medication and provided one or more
efficacy evaluations. The primary efficacy end point was analyzed by using an analysis of
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covariance model (ANCOVA). Factors included age, treatment group, and analysis center
whereas the covariate was the monthly migraine attack rate from the prospective baseline period.
Table 3: Reduction in Monthly Migraine Attack Rate
Placebo

Topiramate 50 mg

Topiramate 100 mg

Migraine attacks per
4.1 (±1.48)
month at baseline
Migraine attacks per
2.4 (±1.93)
month during 12 week
double-blind phase
Reduction in attack
42.3 (±43.15)
rate, %

4.1(±1.74)

4.3 (±1.59)

2.4 (±1.84)

1.3 (±1.23)

34.1 (±55.21)

70.1 (±25.07)

P-Value (vs. placebo)

.798

.016

The Winner et al. study is a randomized, double-blind, placebo-controlled, parallel group
study that took place at 17 medical centers across the United States. There was a 4 week baseline
period, followed by an 8-week titration period and a 12-week maintenance period. The study
evaluated an intent-to-treat (ITT) population and a per-protocol population. The ITT population
was defined as subjects who received at least one dose of medication and had at least one postbaseline efficacy assessment. The per-protocol population consisted of all the subjects who
completed the study without major violations. The primary efficacy analysis compared the
reduction in the number of migraine days per month during the double-blind phase to the
baseline phase in each treatment group of the ITT population. Subjects received topiramate for
an average of 130 days and the average daily dose was 2.0 mg/kg per day. The analysis revealed
that the ITT population had a decreased number of migraine days per month during the doubleblind phase. The mean change from baseline and standard deviation for the ITT population was
2.6 (±2.6) days for the subjects on topiramate. The mean change from baseline for the placebo-
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treated subjects was 2.0 (±3.1) days. The p-value for the ITT population was .061 and was
deemed to be approaching clinical significance. The mean change from baseline for the perprotocol populations was 2.28 (±2.4) days for those on topiramate compared to 2.2 (±2.1) days
for those on the placebo.8 The p-value for the per-protocol population was 0.033 and was
deemed clinically significant. The data from the study is presented below in Table 4.
Table 4: Reduction in monthly migraine days
Placebo

Topiramate

Mean change from baseline
2.0 (±3.1)
for the ITT population
Mean change from baseline
2.2 (±2.1)
for the per-protocol population
Mean monthly migraine days
3.1 (±3.0)
in the last 28 days of the
double-blind phase

2.6 (±2.6)
2.28 (±2.4)
2.4 (±2.8)

Table 5: Reduction in monthly migraine days in all three studies

Mean change from
baseline for the
Lakshmi study
Mean change from
baseline for the Lewis
study
Mean change from
baseline for the perprotocol population in
the Winner Study

Placebo

Topiramate

P-Value

13.38 (±7.48)

16.14 (±9.35)

.02

4.1 (±1.48)

4.3 (±1.59)

.016

2.2 (±2.1)

2.28 (±2.4)

0.033

Each of the studies provided data on the safety of topiramate in their subjects. All three
studies reported some mild to moderate adverse effects. The most frequent adverse effects in the
study by Lakshmi et al. were weight loss (81%), loss of appetite (23.8%), and paresthesias
(23.8%).7 None of the subjects were forced to withdrawal from the study. In the Lewis et al.
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study, the most common adverse effects reported were upper respiratory infections, paresthesia,
and anorexia.3 Six subjects experienced treatment-emergent adverse events, such as fatigue,
nervousness, renal calculus, and epistaxis, and withdrew from the study. In the Winner et al.
study, the most common adverse events reported were upper respiratory infections, anorexia,
weight loss, paresthesias, and somnolence.8 Four subjects in the topiramate group endured severe
adverse events, including infections, severe migraine, and suicidal ideation.
DISCUSSION
This systematic review evaluated the three randomized control trials for the safety and
efficacy of topiramate as preventative measure for children with frequent migraines. The studies
by Lakshmi et al. and Lewis et al. both demonstrated that Topiramate was clinically significant
in reducing the frequency of pediatric migraines. The Lewis et al. study demonstrated on average
a 70% reduction in migraine days per month for those in the Topiramate 100mg/day group
compared to a 34% reduction for those in the Topiramate 50mg/day group. The Winner et al.
study demonstrated a greater reduction in the Topiramate treatment group compared to the
placebo group but the results were not statistically significant. The researchers hypothesized that
the lack of statistical significance may be due to age-related fluctuations in the placebo response.
They noticed that younger patients had a tendency to have a greater response to the placebo.
As mentioned previously, some children are affected by frequent migraines which can
limit their daily activities. One of the issues addressed in the Lakshmi et al. study was school
absenteeism. The results from this study demonstrated a decreased rate of absenteeism after
using topiramate. The average mean at baseline was 4.04 missed school days per month and after
treatment with Topiramate, subjects missed an average of 1.47 school days per month.7
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The researchers in these studies mentioned that one of the limitations in performing an
efficacy analysis on a prophylactic medication is that it takes time for the medication to become
effective. In this sense, the Lakshmi et al. study recommended a study that evaluated subjects for
a longer period of time. Another limitation in the Lakshmi et al. study was the small number of
patients enrolled.
CONCLUSIONS
Topiramate is a safe and effective preventative medication for migraines in children.
Maintaining physical function is one of the benefits of preventing the migraines in children.
They are able to perform their daily activities and attend school. Future studies should be
conducted to investigate the most effective dosing for the age and weight of the child. Since the
studies focus on the pediatric population, it is important to understand the impact adverse effects
can have on the developmental aspects of children. In addition, studies are needed to investigate
the safety of long term use of Topiramate in children. Furthermore, there is a need to discover
the exact mechanism of action behind migraines. Although there are medications that are
effective in preventing and treating migraines, researchers cannot determine the exact reason
why these medications are effective. It would be interesting if scientists could further research
the connection between seizures, migraines, and neurotransmitters. There is a need for continued
research on prophylactic medications for migraines in the pediatric population. It could improve
the quality of life for these children.
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